A bone tissue engineering scaffold with sustained release effect and its preparation method and application
By combining dense layer and loose porous layer structure of hydroxyapatite fiber and gelatin in bone tissue engineering scaffolds, different sequence release of Sr ions and IL-10 is achieved, and the acidity of bone tissue scaffolds after degradation in the prior art is solved. The problems of environmental and release control have achieved effective treatment and bone healing promotion of collusion bone defects.
Patent Information
- Application Number
- CN202310074153.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-01-18
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2043-01-18
AI Technical Summary
Existing bone tissue scaffolds may lead to a local acidic environment that aggravates inflammation after degradation, cannot effectively target collusion bone defects, and difficult to control the release of Sr ions and IL-10, limiting their application in bone healing.
A bone tissue engineering scaffold consisting of an outer dense layer and an intermediate loose porous layer was designed. The dense layer is composed of hydroxyapatite fibers loaded with metal ions and gelatin. The loose porous layer is composed of gelatin, and hydroxyphosphorus is synthesized through hydrothermal conditions. Greystone fibers are spatially distributed in the material, and Sr ions and IL-10 are achieved in different orders of their release.
This scaffold has good biocompatibility and sustained release performance, can effectively prevent the growth of fibroblasts, promote the differentiation and bone healing of osteoblasts, provide early anti-inflammatory and later high-efficiency bone formation effects, and is suitable for a variety of bone defects Treatment, low cost and easy to operate.
Smart Images

Figure CN115998958B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomaterials, and in particular relates to a bone tissue engineering scaffold with sustained-release effect, and a preparation method and application thereof. Background Art
[0002] The information disclosed in this background technology section is only intended to enhance understanding of the overall background of the invention and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to those skilled in the art.
[0003] The use of biological scaffolds is a common and popular biomaterial strategy for treating tissue defects. An ideal bone scaffold must firstly possess excellent biocompatibility and produce metabolic products that are harmless to the human body. Secondly, it should be able to induce bone remodeling and provide a favorable microenvironment for local bone remodeling. Currently, a variety of biomaterials have been used to construct bone scaffolds, such as poly(lactic-co-glycolic acid) (PLGA), hydroxyapatite, and hydrogels. However, these scaffolds still present numerous challenges. Degradation of some scaffold components (e.g., PLGA) can create a localized acidic environment, exacerbating local inflammation and hindering osteogenesis. Alternatively, during application, due to their lack of biological barrier function, fibroblasts may infiltrate during bone healing, ultimately leading to a decrease in bone mass. Despite the availability of various scaffold morphologies, they remain inadequate for the treatment of various common bone defects encountered clinically, such as interdigitating bone defects, which are common in the maxillofacial and oral regions. Interdigitating bone defects are a clinically challenging hard tissue defect with a poor prognosis and a lack of bone source. Therefore, seeking a biological scaffold for personalized treatment of intermittent bone defects has important practical significance for the clinical treatment of such patients.
[0004] Among common biomaterials, hydroxyapatite (HA or HAP) is a major component of human bones and teeth. Biologically, it is widely used in various bone tissue scaffolds due to its excellent biocompatibility, osteoconductivity, bioactivity, biodegradability, and low cost. Gelatin (GA), a partially hydrolyzed product of collagen, is also widely used clinically due to its excellent biocompatibility and biodegradability. Current research suggests that strontium (Sr) ions have multiple promoting effects on the in vivo osteogenesis process, primarily by inducing early vascularization, promoting osteoblast differentiation, and bone matrix formation, thereby promoting bone tissue reconstruction within bone defects. Interleukin-10 (IL-10) is a common anti-inflammatory factor in the human body. It has anti-inflammatory effects in the early stages of osteogenesis, reducing osteoclast activity, and promoting the transformation of M1 monocytes to M2 monocytes. Local administration of IL-10 can reduce the loss of surrounding bone tissue during the early stages of bone remodeling. However, high concentrations of Sr ions can cause damage to the human body, and local rapid injection of large amounts of IL-10 can inhibit bone formation. Therefore, how to effectively utilize the above materials to construct an osteoinductive scaffold specifically for coherent bone defects and control the release of Sr ions and IL-10 still requires a specific and feasible design plan. Summary of the Invention
[0005] In order to address the deficiencies of the prior art, the present invention aims to provide a bone tissue engineering scaffold with sustained-release effect, as well as its preparation method and application. The bone tissue engineering scaffold provided by the present invention has sustained-release function and the efficacy of promoting bone tissue repair and reconstruction, is low in price, and its metabolic products are harmless to the human body and have good biocompatibility.
[0006] In order to achieve the above object, the technical solution of the present invention is:
[0007] The first aspect of the present invention provides a bone tissue engineering scaffold with a sustained release effect, wherein the bone tissue engineering scaffold is composed of two outer dense layers and a middle loose porous layer;
[0008] The dense layer is composed of hydroxyapatite fibers loaded with metal ions and gelatin; and the loose porous layer is composed of gelatin.
[0009] A second aspect of the present invention provides a method for preparing the above-mentioned bone tissue engineering scaffold, comprising the following steps:
[0010] 1) Under hydrothermal conditions, hydroxyapatite fibers are synthesized using an aqueous solution containing a water-soluble calcium salt and a water-soluble metal salt and an aqueous solution containing a water-soluble phosphorus source; the hydroxyapatite fibers are dispersed in alcohol and filtered to obtain a hydroxyapatite fiber membrane; a gelatin solution is poured on both sides of the hydroxyapatite fiber membrane, dried, and chemically cross-linked to obtain a dense layer;
[0011] The water-soluble metal salt is one of water-soluble metal salts of Sr, Cu, Zn, Mn or Mg;
[0012] 2) Paraffin microspheres with a diameter of 300-500 μm are heated and connected to form a paraffin sphere template, a gelatin solution is injected into the paraffin sphere template under negative pressure, phase separation is performed, and the template is soaked in ethanol and 1,4-dioxane, freeze-dried, the paraffin microspheres are dissolved in n-hexane, the n-hexane is exchanged for cyclohexane, freeze-dried, chemically cross-linked, washed, and freeze-dried again to obtain a loose porous layer;
[0013] 3) Cut the dense layer and the loose porous layer, combine them in a gelatin solution, dry them, and cross-link them.
[0014] The preparation method of the bone tissue engineering scaffold of the present invention has simple process, is easy to operate, and uses cheap and readily available raw materials, thereby having low cost.
[0015] The bone tissue engineering scaffold provided by the present invention has a unique microscopic morphology. Its dense layer effectively prevents fibroblast in-growth, while its loose, porous layer has an appropriate pore size to facilitate osteoblast infiltration. Furthermore, its components are free of harmful substances and exhibit strong biocompatibility. Therefore, a third aspect of the present invention provides the use of the aforementioned bone tissue engineering scaffold in the preparation of a product for treating bone tissue defects.
[0016] The inventive concept of the present invention:
[0017] The inventors of this application have conducted extensive and in-depth research based on clinical needs. They found that Sr ions can promote the osteogenesis process, mainly affecting the osteogenesis phase of bone tissue reconstruction. Therefore, the shorter the early inflammatory phase, the more obvious the effect of Sr ions. Considering that IL-10 has a good anti-inflammatory effect and participates in and regulates the inflammatory phase in the early stage of bone reconstruction, it is used as an intervention method to shorten the inflammatory phase. In order to achieve different spatial distributions of the two in the material and different time series release in the body, Sr-doped hydroxyapatite fibers are compounded into the dense layer, and IL-10 is injected into the loose porous layer in the middle. The purpose of different time series release in the body is achieved through two release means, thereby preparing a composite scaffold that can significantly promote bone tissue repair and promote the differentiation of osteoblast-related cells, achieving "active anti-inflammatory in the early stage and efficient osteogenesis in the later stage".
[0018] The beneficial effects of the present invention are:
[0019] (1) The bone tissue engineering scaffold with sustained release provided by the present invention is composed of a dense layer composed of hydroxyapatite fibers and gelatin and a loose porous layer constructed of gelatin. The composition does not contain harmful substances, has strong biocompatibility, and is made in a structure modeled after the structure of normal human bones. It can better reproduce the microstructure of the penetrating bone defect and facilitate the recovery of the microstructure during the healing process.
[0020] (2) The bone tissue engineering scaffold with sustained release provided by the present invention has a unique microscopic appearance. The dense layer can effectively prevent the growth of fibroblasts, and the loose porous layer has an appropriate pore size (300-500μm), which is convenient for osteoblasts to crawl in. The design of the scaffold is also very flexible. Hydroxyapatite fibers doped with different metal ions can be used to load the dense layer with different metal ions, and the loose porous layer can be injected with different biological factors, thereby giving the scaffold different functions. After being loaded with Sr ions and IL-10, it showed good anti-inflammatory effects and osteogenic properties, which is beneficial to its subsequent application in the biomedical field. It can be used as a drug sustained release carrier, bone filling material, and bone guidance material, etc., and has a broad application prospect.
[0021] (3) The bone tissue scaffold of the present invention can load different metal ions and growth factors, is flexible and versatile, and has diverse functions. It can adapt to various clinical bone defects through the replacement of ions and drugs and produce multiple effects, thereby fully meeting clinical needs.
[0022] (4) The preparation method of the present invention has a simple process, is easy to operate, and the raw materials used are cheap and easily available, so the cost is low. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] The accompanying drawings, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.
[0024] Figure 1 This is an electron micrograph of the bone tissue engineering scaffold with sustained release effect produced in Example 1 of the present invention;
[0025] Figure 2 is the Sr ion release curve;
[0026] Figure 3 is the curved line of Ca ion release;
[0027] Figure 4 is the release curve of IL-10;
[0028] Figure 5 This is a statistical chart of cell proliferation experiment results;
[0029] Figure 6Figure 2 shows the effects of different scaffolds on the activity of mouse osteoblast precursor cells in vitro. (a) shows the live-dead staining results of the three scaffolds: HA scaffold, SrHA scaffold, and IL-10@SrHA scaffold; (b) shows the FSEM electron microscopy results of the three scaffolds.
[0030] Figure 7 Figure 3 shows the effects of different scaffolds on the osteogenic differentiation of mouse osteoblast precursor cells in vitro. (a) shows the ALP staining results of the three scaffolds: HA scaffold, SrHA scaffold, and IL-10@SrHA scaffold; (b) shows the Alizarin Red staining results of the three scaffolds.
[0031] Figure 8 Graph showing the effects of different scaffolds on the activity of mouse osteoblast precursor cells in vivo, where a is the HE staining results of the three scaffolds: HA scaffold, SrHA scaffold, and IL-10@SrHA scaffold; and b is the Goldner trichrome staining results of the three scaffolds. DETAILED DESCRIPTION
[0032] In view of the current lack of osteogenic induction scaffolds specifically for treating intermittent bone defects, the present invention proposes a bone tissue engineering scaffold with sustained release effect, and a preparation method and application thereof.
[0033] In one embodiment of the present invention, a bone tissue engineering scaffold with sustained release is provided, wherein the bone tissue engineering scaffold is composed of two outer dense layers and a middle loose porous layer;
[0034] The dense layer is composed of a composite of metal ion-loaded hydroxyapatite fibers and gelatin; the loose porous layer is composed of gelatin. The bone tissue engineering scaffold provided by the present invention has a sustained release function and the efficacy of promoting bone tissue repair and reconstruction. The scaffold is low-cost and has good biocompatibility.
[0035] In another specific embodiment of the present invention, the pore size of the loose porous layer is 300-500 μm, preferably 315-400 μm. Osteoblasts are relatively large, with diameters of 20-40 μm, and are oblong or irregular in shape, occurring singly or in clusters. The pore size of the loose porous layer is set to 300-500 μm, which is an appropriate pore size and is very convenient for osteoblasts to crawl into.
[0036] In another embodiment of the present invention, the thickness of the dense layer is 0.5-0.75 mm. The dense layer has a biological barrier function and can effectively isolate the in-growth of fibroblasts during the bone healing process.
[0037] In another embodiment of the present invention, the metal ion loaded on the hydroxyapatite fiber is one of Sr, Cu, Zn, Mn, and Mg; preferably Sr;
[0038] More preferably, the doping amount of Sr is 2-10 wt% of the hydroxyapatite fiber; more preferably 8 wt%, as this doping amount has the best osteoinduction effect on the bone tissue scaffold.
[0039] In another specific embodiment of the present invention, the loose porous layers are filled with growth factors; the growth factors are one or more combinations of bone morphogenetic protein, transforming growth factor-β, vascular endothelial growth factor, platelet-derived growth factor, interleukin and angiopoietin.
[0040] More preferably, the interleukins include IL-1, IL-8, IL-10, and IL-15; more preferably, IL-10.
[0041] The bone tissue engineering scaffold of the present invention can be loaded with different metal ions and growth factors or drugs. It is flexible and versatile, and can adapt to various clinical bone defects by replacing ions and growth factors, and produce multiple effects, thereby fully meeting clinical needs.
[0042] In another embodiment of the present invention, a method for preparing the above-mentioned bone tissue engineering scaffold is provided, comprising the following steps:
[0043] 1) Under hydrothermal conditions, hydroxyapatite fibers are synthesized using an aqueous solution containing a water-soluble calcium salt and a water-soluble metal salt and an aqueous solution containing a water-soluble phosphorus source; the hydroxyapatite fibers are dispersed in alcohol and filtered to obtain a hydroxyapatite fiber membrane; a gelatin solution is poured on both sides of the hydroxyapatite fiber membrane, dried, and chemically cross-linked to obtain a dense layer;
[0044] The water-soluble metal salt is one of water-soluble metal salts of Sr, Cu, Zn, Mn or Mg;
[0045] 2) Paraffin microspheres with a diameter of 300-500 μm are heated and connected to form a paraffin sphere template, a gelatin solution is injected into the paraffin sphere template under negative pressure, phase separation is performed, and the template is soaked in ethanol and 1,4-dioxane, freeze-dried, the paraffin microspheres are dissolved in n-hexane, the n-hexane is exchanged for cyclohexane, freeze-dried, chemically cross-linked, washed, and freeze-dried again to obtain a loose porous layer;
[0046] 3) Cut the dense layer and the loose porous layer, combine them in a gelatin solution, dry them, and cross-link them.
[0047] In another embodiment of the present invention, the synthetic hydroxyapatite fiber is specifically:
[0048] Oleic acid, ethanol and deionized water are mixed into a ternary solvent, and a water-soluble calcium salt and a water-soluble strontium salt aqueous solution, an alkaline catalyst aqueous solution and a water-soluble phosphorus source aqueous solution are sequentially added dropwise, and the mixture is reacted at high temperature to obtain hydroxyapatite fiber.
[0049] The volume ratio of oleic acid, ethanol and deionized water is 10-15:10-15:8-12.
[0050] Wherein, in the aqueous solution containing water-soluble calcium salt and water-soluble strontium salt, the concentration of water-soluble calcium salt is 15-30 mg / mL, and the concentration of water-soluble metal salt is 3-5 mg / mL.
[0051] The alkaline catalyst aqueous solution is a strong alkali aqueous solution with a concentration of 40-60 mg / mL.
[0052] Wherein, the concentration of the water-soluble phosphorus source in the aqueous solution containing the water-soluble phosphorus source is 30-40 mg / mL.
[0053] The volume ratio of the ternary solvent, the aqueous solution containing water-soluble calcium salt and water-soluble strontium salt, the aqueous solution of the alkaline catalyst and the aqueous solution containing water-soluble phosphorus source is 1-2:1-2:1-2::1-2.
[0054] The dripping interval of the three aqueous solutions is 15-30 minutes.
[0055] The high temperature reaction conditions are: 150-200°C for 20-30h, more preferably 180°C for 24h.
[0056] In another embodiment of the present invention, the preparation method further comprises: injecting or dripping the growth factor solution into the loose porous layer of the bone tissue engineering scaffold.
[0057] In another embodiment of the present invention, the growth factor solution is an IL-10 solution with a concentration of 0.5-1 ng / μL, which is injected or added dropwise until the growth factor solution completely wets the loose porous layer.
[0058] In another embodiment of the present invention, the paraffin microspheres are prepared by pouring a paraffin liquid into a polyvinyl alcohol aqueous solution and stirring, pouring ice water into the solution to solidify the paraffin microspheres, and washing and screening the paraffin microspheres to obtain the paraffin microspheres with a suitable particle size.
[0059] In another embodiment of the present invention, there is provided a use of the above-mentioned bone tissue engineering scaffold in the preparation of a product for treating bone tissue defects.
[0060] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below with reference to specific embodiments.
[0061] The methods described in the following examples are conventional methods unless otherwise specified, and the reagents described are commercially available unless otherwise specified.
[0062] Example 1
[0063] A method for preparing a bone tissue engineering scaffold with sustained release effect comprises the following steps:
[0064] (1) Preparation of hydroxyapatite fibers: 12 ml of oleic acid, 11 ml of ethanol, and 10 ml of deionized water were mixed in a closed system to form a mixture under magnetic stirring. Then, an aqueous solution (20 mL) containing CaCl2 (0.4085 g) and SrCl2·6H2O (0.0853 g), an aqueous solution (20 mL) containing NaOH (1.00 g), and an aqueous solution (20 mL) containing NaH2PO4·2H2O (0.66 g) were added dropwise, respectively. The dropwise addition interval of the three aqueous solutions was 25 min. Finally, the obtained mixture was poured into a Teflon-lined stainless steel autoclave and kept at a constant temperature of 180°C for 24 h. After the autoclave was cooled to room temperature, the product was washed three times with ethanol and deionized water, then collected by centrifugation and finally dried in vacuo to obtain 8 wt% Sr-doped hydroxyapatite nanofibers.
[0065] (2) Preparation of dense layers on both sides: 2.0 g of Sr-doped hydroxyapatite nanofibers were dispersed in 50 mL of ethanol and ultrasonically treated to form a nanofiber slurry. The nanofiber slurry was then filtered to form a paper-like film and then vacuum dried. At the same time, gelatin powder (2.5 g) was dissolved in a mixed solvent of ethanol (10 ml) and deionized water (10 ml) at 40 °C to obtain a gelatin solution. The gelatin solution was then cast on one side of the Sr-doped hydroxyapatite fiber membrane, dried at 40 °C for 10 min, and then cast on the other side to form a composite material. The composite material was dried at 40 °C for 120 min to prepare a SrHA / gelatin dense layer. Finally, the HA / gelatin dense layer was chemically cross-linked with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide salt base (EDC, 98.5%) and N-hydroxysuccinimide (NHS, 98%) in ethanol at 20 °C for 36 h. After chemical cross-linking was completed, the Sr0HA / gelatin dense layer was washed three times with deionized water and dried in a freeze dryer.
[0066] (3) Preparation of paraffin balls: 0.6 g of polyvinyl alcohol (PVA) was dissolved in deionized water (100 mL) to prepare a PVA solution. 20 g of paraffin was heated until melted, and then microemulsified in a PVA solution at 70 °C and stirred evenly. Subsequently, the resulting mixture was poured into ice water to solidify the paraffin microdroplets into paraffin balls. The paraffin balls were washed and sieved with deionized water and ethanol to screen out paraffin balls with a size of 315-400 μm. Finally, the paraffin balls of this size were placed in a freeze dryer and dried and stored at 4 °C for later use.
[0067] (4) Preparation of loose porous layer: Take 2.0 g of paraffin balls from step (3), stack them in a mold, and heat them at 37°C for 20 minutes to form a paraffin ball template. 1.5 g of gelatin powder is dissolved in a mixture of ethanol (10 ml) and deionized water (10 ml) to obtain a gelatin solution at 40°C. The gelatin solution (2 ml) is cast on the assembled paraffin ball template. The mold containing the gelatin solution and the assembled paraffin ball template is transferred to a low vacuum environment, and the gelatin solution is injected into the paraffin ball template, and phase separation is carried out at -40°C for 6 hours. After phase separation, the mold is soaked in anhydrous ethanol at -18°C for 24 hours, and then immersed in 1,4-dioxane for 24 hours. Subsequently, the gelatin / paraffin composite material is removed from the mold and transferred to a -18°C refrigerator for freezing for 12 hours until the composite material is completely frozen. The frozen gelatin / paraffin composite was freeze-dried in a freeze dryer for 36 hours. The dried composite was then immersed in n-hexane to remove the paraffin. The resulting porous scaffold was then immersed in cyclohexane for solvent exchange to remove the n-hexane. After solvent exchange, the scaffold was frozen at -18°C for 12 hours and then freeze-dried in a freeze dryer for 36 hours. Finally, the freeze-dried porous scaffold was chemically cross-linked for 24 hours by immersing it in a mixed solvent consisting of a morpholineethanesulfonic acid solution (pH = 5.3, 0.05 mol / L) containing EDC and NHS and acetone. After chemical cross-linking, the scaffold was rinsed three times with deionized water, then frozen at -18°C for 12 hours and freeze-dried in a freeze dryer for 36 hours. This completed the desired loose porous layer.
[0068] (5) IL-10 loading: 100 μL of 0.5 ng / μL IL-10 solution (α-MEM medium) was injected into the porous layer using a 1 ml sterile syringe and a sterile needle. The needle was inserted approximately 2 mm into the porous layer. The injection was completed in one go. The solution completely wetted the porous layer, leaving no excess solution.
[0069] (6) Cutting the dense layer and the loose porous layer loaded with IL-10, combining the two in a gelatin solution, drying, and cross-linking to obtain a bone tissue engineering scaffold with a sustained release effect.
[0070] Example 2
[0071] A method for preparing a bone tissue engineering scaffold with sustained release effect comprises the following steps:
[0072] (1) Preparation of hydroxyapatite fibers: 12 ml of oleic acid, 11 ml of ethanol, and 10 ml of deionized water were mixed in a closed system to form a mixture under magnetic stirring. Then, an aqueous solution (20 mL) containing CaCl2 (0.4464 g) and SrCl2·6H2O (0.0427 g), an aqueous solution (20 mL) containing NaOH (1.00 g), and an aqueous solution (20 mL) containing NaH2PO4·2H2O (0.66 g) were added dropwise, respectively. The dropwise addition interval of the three aqueous solutions was 25 min. Finally, the obtained mixture was poured into a Teflon-lined stainless steel autoclave and kept at a constant temperature of 180°C for 24 h. After the autoclave was cooled to room temperature, the product was washed three times with ethanol and deionized water, then collected by centrifugation and finally dried in vacuo to obtain 4 wt% Sr-doped hydroxyapatite nanofibers.
[0073] (2) Preparation of dense layers on both sides: 2.0 g of Sr-doped hydroxyapatite nanofibers were dispersed in 50 mL of ethanol and ultrasonically treated to form a nanofiber slurry. The nanofiber slurry was then filtered to form a paper-like film and then vacuum dried. At the same time, gelatin powder (2.5 g) was dissolved in a mixed solvent of ethanol (10 ml) and deionized water (10 ml) at 40 °C to obtain a gelatin solution. The gelatin solution was then cast on one side of the Sr-doped hydroxyapatite fiber membrane, dried at 40 °C for 10 min, and then cast on the other side to form a composite material. The composite material was dried at 40 °C for 120 min to prepare a SrHA / gelatin dense layer. Finally, the HA / gelatin dense layer was chemically cross-linked with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide salt base (EDC, 98.5%) and N-hydroxysuccinimide (NHS, 98%) in ethanol at 20 °C for 36 h. After chemical cross-linking was completed, the Sr0HA / gelatin dense layer was washed three times with deionized water and dried in a freeze dryer.
[0074] (3) Preparation of paraffin balls: 0.6 g of polyvinyl alcohol (PVA) was dissolved in deionized water (100 mL) to prepare a PVA solution. 20 g of paraffin was heated until melted, and then microemulsified in a PVA solution at 70 °C and stirred evenly. Subsequently, the resulting mixture was poured into ice water to solidify the paraffin microdroplets into paraffin balls. The paraffin balls were washed and sieved with deionized water and ethanol to screen out paraffin balls with a size of 315-400 μm. Finally, the paraffin balls of this size were placed in a freeze dryer and dried and stored at 4 °C for later use.
[0075] (4) Preparation of loose porous layer: Take 2.0 g of paraffin balls from step (3), stack them in a mold, and heat them at 37°C for 20 minutes to form a paraffin ball template. 1.5 g of gelatin powder is dissolved in a mixture of ethanol (10 ml) and deionized water (10 ml) to obtain a gelatin solution at 40°C. The gelatin solution (2 ml) is cast on the assembled paraffin ball template. The mold containing the gelatin solution and the assembled paraffin ball template is transferred to a low vacuum environment, and the gelatin solution is injected into the paraffin ball template, and phase separation is carried out at -40°C for 6 hours. After phase separation, the mold is soaked in anhydrous ethanol at -18°C for 24 hours, and then immersed in 1,4-dioxane for 24 hours. Subsequently, the gelatin / paraffin composite material is removed from the mold and transferred to a -18°C refrigerator for freezing for 12 hours until the composite material is completely frozen. The frozen gelatin / paraffin composite was freeze-dried in a freeze dryer for 36 hours. The dried composite was then immersed in n-hexane to remove the paraffin. The resulting porous scaffold was then immersed in cyclohexane for solvent exchange. After solvent exchange, it was frozen at -18°C for 12 hours and then freeze-dried in a freeze dryer for 36 hours. Finally, the freeze-dried porous scaffold was chemically cross-linked for 24 hours by immersing it in a mixed solvent consisting of a morpholineethanesulfonic acid solution (pH = 5.3, 0.05 mol / L) containing EDC and NHS and acetone. After chemical cross-linking, the scaffold was rinsed three times with deionized water, then frozen at -18°C for 12 hours and freeze-dried in a freeze dryer for 36 hours. This completed the desired loose porous layer.
[0076] (5) IL-10 loading: 50 μl of 1 ng / μl IL-10 solution was added dropwise to the gelatin porous layer using a 200 μl pipette. The solution was added using α-MEM medium. The needle was inserted approximately 2 mm into the porous layer. The injection was completed in one go. The solution completely wetted the porous layer, leaving no excess solution.
[0077] (6) Cutting the dense layer and the loose porous layer loaded with IL-10, combining the two in a gelatin solution, drying, and cross-linking to obtain a bone tissue engineering scaffold with a sustained release effect.
[0078] Example 3
[0079] A method for preparing a bone tissue engineering scaffold with sustained release effect comprises the following steps:
[0080] The difference from Example 1 is:
[0081] Loading of IL-10: Inject 50 μL of a 1 ng / μL IL-10 solution in α-MEM medium into the porous layer using a 1 ml sterile syringe and sterile needle. Insert the needle approximately 2 mm into the porous layer. Complete the injection in one go. Ensure the solution completely wets the porous layer, with no excess solution spilling out.
[0082] Comparative Example 1
[0083] A method for preparing a scaffold composed of hydroxyapatite nanofibers with a Sr ion content of 0 wt% (HA scaffold) comprises the following steps:
[0084] The difference from Example 1 is that Sr is not doped and IL-10 is not injected.
[0085] Comparative Example 2
[0086] A method for preparing a scaffold composed of hydroxyapatite nanofibers with an Sr ion content of 8 wt% (SrHA scaffold) comprises the following steps:
[0087] The difference from Example 1 is that IL-10 was not injected.
[0088] Application Example 1
[0089] In this application example, we investigated the effects of IL-10-loaded strontium-containing bone tissue engineering scaffolds on the biological activity of mouse osteoblast precursor cells (MC3T3-E1 cell line) through in vitro experiments. In vivo experiments investigated the bone remodeling effects of IL-10-loaded strontium-containing bone tissue engineering scaffolds on rabbit mandibular defects. The scaffolds obtained in Example 3, Comparative Example 1, and Comparative Example 2 were used for testing. The scaffold obtained in Example 3 was designated IL-10@SrHA scaffold, the scaffold obtained in Comparative Example 1 was designated HA scaffold, and the scaffold obtained in Comparative Example 2 was designated SrHA scaffold.
[0090] 1.1 In vitro release assay of Ca and Sr ions:
[0091] Three prepared composite scaffolds (HA scaffold, SrHA scaffold, and IL-10@SrHA scaffold) were immersed in PBS (pH = 7.4) and then placed in a thermostatic shaker maintained at 37°C with continuous shaking (100 rpm). The ratio of PBS solution volume to composite scaffold volume was 1 ml / mg. Release media were extracted after immersion for 1, 4, 7, 14, and 21 days. The release behavior of Ca and Sr ions was analyzed by inductively coupled plasma mass spectrometry (ICP-MS). Three replicate samples were collected from each group and the average value was calculated.
[0092] 1.2 IL-10 release detection:
[0093] The IL-10-containing scaffold (IL-10@SrHA scaffold) was placed in a 15ml centrifuge tube, 2ml of PBS (pH 7.4) was added, and the tube was incubated at 37°C. Samples were taken after immersion for 1, 3, 6, 12, and 24 hours and replenished with fresh solution. The removed solution was assayed for IL-10 content using an ELISA kit (Biyuntian) according to the manufacturer's instructions, and the cumulative percentage of IL-10 released from the material was calculated at different time points.
[0094] 1.3 Cell proliferation assay:
[0095] Sterile HA scaffolds, SrHA scaffolds, and IL-10@SrHA scaffolds were placed in 12-well plates and seeded with MC3T3-E1 cells at a density of 30,000 cells per well. The plates were then cultured in a constant-temperature cell incubator. Cell proliferation on the materials was evaluated using the CCK-8 assay after 1, 3, and 5 days of culture.
[0096] 1.4 Fluorescence observation:
[0097] After the cells from the cell proliferation experiment in 1.3 were cultured on the HA scaffold, SrHA scaffold, and IL-10@SrHA scaffold for three days, they were stained with the AM / PI cell live / dead staining kit and placed in a constant temperature incubator for 30 minutes. The cells were then observed and photographed using a fluorescence microscope.
[0098] 1.5FSEM observation:
[0099] After the cells in the cell proliferation experiment in 1.3 were cultured on the HA scaffold, SrHA scaffold, and IL-10@SrHA scaffold for 3 days, they were fixed with 4% paraformaldehyde, dehydrated with gradient ethanol, and dried. The growth of cells on different scaffolds was then observed using a field emission scanning electron microscope (FSEM) and photographed.
[0100] 1.6 Effect of scaffolds on the biological activity of mouse osteoblast precursor cells (MC3T3-E1 cell line):
[0101] MC3T3-E1 cells were seeded onto HA scaffolds, SrHA scaffolds, and IL-10@SrHA scaffolds, respectively, and incubated in a constant-temperature incubator for 3 days. The same volume of osteogenic induction medium was then added. The induction medium was regularly replaced on days 14 and 21 of culture. ALP activity and the number of calcium nodules in the samples were determined according to the instructions of the ALP and Alizarin Red staining kits.
[0102] 1.7 In vivo experiments
[0103] Sterile HA scaffolds, SrHA scaffolds, and IL-10@SrHA scaffolds were implanted into artificially created mandibular defects in rabbits. After eight weeks of implantation, samples were removed from each group. The samples were fixed with 4% paraformaldehyde and then dehydrated using graded ethanol. Tissue sections were obtained and stained with hematoxylin and eosin (H&E) and Goldner's trichrome. The tissues were then observed and imaged under a light microscope.
[0104] 1.7 Conclusion:
[0105] (1) The tests in 1.1 and 1.2 verified the release pattern of each active ingredient of the stent under in vitro conditions. The specific results are as follows: Figure 2 、 3 , as shown in 4.
[0106] Depend on Figure 2 、 3 , 4 It can be seen that: Sr ions and Ca ions maintain long-term stable release and maintain a high concentration after 21 days, which shows that the scaffold can improve the microenvironment at the implantation site for a long time after implantation, provide sufficient Ca ions and Sr ions to promote osteogenesis; IL-10 is released by about 90% within 24 hours of loading, and the release curve is relatively flat, with no explosive release trend found, indicating that it can play an effective anti-inflammatory role in the early stage of implantation.
[0107] (2) The tests in 1.3, 1.4 and 1.5 verified the effects of different scaffolds on the activity of mouse osteoblast precursor cells in vitro. The specific results are as follows: Figure 5 、 6 shown.
[0108] Depend on Figure 5 and Figure 6 Compared to HA scaffolds, MC3T3-E1 cells exhibited better proliferation on SrHA and IL-10@SrHA scaffolds. Cell activity was highest on the IL-10@SrHA scaffold surface, with the highest absorbance at 450nm across all time periods. Pseudopodia on the SrHA and IL-10@SrHA scaffolds were also longer, with some extending into the scaffold interior and tightly binding to the scaffold's porous layer. These results indicate that the addition of Sr ions and IL-10 promotes cell growth and differentiation on the scaffolds.
[0109] (3) The test in 1.6 verified the effects of different scaffolds on the osteogenic differentiation of mouse osteoblast precursor cells in vitro. The specific results are as follows: Figure 7 shown.
[0110] Depend on Figure 7It can be seen that SrHA scaffold material can promote the expression of ALP and the formation of calcium nodules in MC3T3-E1, and IL-10@SrHA scaffold shows the strongest promoting effect. These results indicate that scaffold materials loaded with Sr ions and IL-10 at the same time have stronger osteogenic ability compared with scaffolds used alone or scaffolds loaded with Sr ions alone.
[0111] (4) The test in 1.7 verified the effects of different scaffolds on the activity of mouse osteoblast precursor cells in vivo. The specific results are as follows: Figure 8 shown.
[0112] Depend on Figure 8 It can be seen that 8 weeks after each group of scaffold materials were implanted into the rabbit mandible, it was observed that the SrHA scaffold and IL-10@SrHA scaffold groups showed more bone formation around the HA scaffold group than the HA scaffold group, and the bone microstructure of the IL-10@SrHA scaffold was better, indicating that the simultaneous loading of Sr ions and IL-10 is beneficial to the remodeling of bone tissue.
[0113] The foregoing description is merely a preferred embodiment of the present invention and is not intended to limit the present invention. Those skilled in the art will readily appreciate that various modifications and variations of the present invention are possible. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the present invention are intended to be within the scope of protection of the present invention.
Claims
1. A bone tissue engineering scaffold with sustained release effect, characterized in that: The bone tissue engineering scaffold is composed of two outer dense layers and a middle loose porous layer; The dense layer is composed of hydroxyapatite fibers loaded with metal ions and gelatin; the loose porous layer is composed of gelatin; The metal ion in the hydroxyapatite fiber is one of Sr, Cu, Zn, Mn or Mg; The loose porous layers are filled with growth factors; The method for preparing the bone tissue engineering scaffold comprises the following steps: 1) Under hydrothermal conditions, hydroxyapatite fibers are synthesized using an aqueous solution containing a water-soluble calcium salt and a water-soluble metal salt and an aqueous solution containing a water-soluble phosphorus source; the hydroxyapatite fibers are dispersed in alcohol and filtered to obtain a hydroxyapatite fiber membrane; a gelatin solution is poured on both sides of the hydroxyapatite fiber membrane, dried, and chemically cross-linked to obtain a dense layer; 2) heating and connecting paraffin microspheres with a diameter of 300-500 μm to form a paraffin sphere template, injecting a gelatin solution into the paraffin sphere template under negative pressure, phase separation, soaking in ethanol and 1,4-dioxane in sequence, freeze-drying, dissolving the paraffin spheres with n-hexane, exchanging n-hexane with cyclohexane, freeze-drying, chemically cross-linking, washing, and freeze-drying again to obtain a loose porous layer; 3) Cut the dense layer and the loose porous layer, combine them in a gelatin solution, dry and cross-link them.
2. The bone tissue engineering scaffold according to claim 1, characterized in that: The pore size of the loose porous layer is 300-500 μm; the thickness of the dense layer is 0.5-0.75 mm.
3. The bone tissue engineering scaffold according to claim 2, characterized in that: The pore size of the loose porous layer is 315-400 μm.
4. The bone tissue engineering scaffold according to claim 1, characterized in that: The metal ion in the hydroxyapatite fiber is Sr; the doping amount of Sr is 2-10wt% of the hydroxyapatite fiber.
5. The bone tissue engineering scaffold according to claim 4, characterized in that: The doping amount of Sr is 8 wt% of the hydroxyapatite fiber.
6. The bone tissue engineering scaffold according to claim 1, characterized in that: The growth factor is one or more combinations of bone morphogenetic protein, transforming growth factor-β, vascular endothelial growth factor, platelet-derived growth factor, interleukin and angiogenin; The interleukins include IL-1, IL-8, IL-10, and IL-15.
7. The bone tissue engineering scaffold according to claim 6, characterized in that: The interleukin is IL-10.
8. The method for preparing the bone tissue engineering scaffold according to any one of claims 1 to 7, characterized in that: The following steps are involved: 1) under hydrothermal conditions, synthesizing hydroxyapatite fibers using an aqueous solution containing a water-soluble calcium salt and a water-soluble metal salt and an aqueous solution containing a water-soluble phosphorus source; The hydroxyapatite fiber is dispersed in alcohol and filtered to obtain a hydroxyapatite fiber membrane; The gelatin solution is poured on both sides of the hydroxyapatite fiber membrane, dried, and chemically cross-linked to obtain a dense layer; The water-soluble metal salt is one of water-soluble metal salts of Sr, Cu, Zn, Mn or Mg; 2) heating and connecting paraffin microspheres with a diameter of 300-500 μm to form a paraffin sphere template, injecting a gelatin solution into the paraffin sphere template under negative pressure, phase separation, soaking in ethanol and 1,4-dioxane in sequence, freeze-drying, dissolving the paraffin spheres with n-hexane, exchanging n-hexane with cyclohexane, freeze-drying, chemically cross-linking, washing, and freeze-drying again to obtain a loose porous layer; 3) Cut the dense layer and the loose porous layer, combine them in a gelatin solution, dry and cross-link them.
9. The preparation method according to claim 8, characterized in that: The synthesis of hydroxyapatite fiber is specifically as follows: oleic acid, ethanol and deionized water are mixed into a ternary solvent, and a water-soluble calcium salt and a water-soluble strontium salt aqueous solution, an alkaline catalyst aqueous solution and a water-soluble phosphorus source aqueous solution are sequentially added dropwise, and the hydroxyapatite fiber is obtained by high temperature reaction; The volume ratio of oleic acid, ethanol and deionized water is 10-15:10-15:8-12; In the aqueous solution containing water-soluble calcium salt and water-soluble strontium salt, the concentration of water-soluble calcium salt is 15-30 mg / mL, and the concentration of water-soluble strontium salt is 3-5 mg / mL; The alkaline catalyst aqueous solution is a strong alkali aqueous solution with a concentration of 40-60 mg / mL; The aqueous solution containing a water-soluble phosphorus source has a concentration of 30-40 mg / mL; The volume ratio of the ternary solvent, the aqueous solution containing a water-soluble calcium salt and a water-soluble strontium salt, the aqueous solution of the alkaline catalyst and the aqueous solution containing a water-soluble phosphorus source is 1-2:1-2:1-2:1-2; The infusion interval of the three aqueous solutions was 15-30 min; The high temperature reaction conditions are: 150-200°C, reaction time 20-30h.
10. The preparation method according to claim 9, characterized in that The high temperature reaction conditions are 180°C for 24 hours.
11. The preparation method according to claim 9, characterized in that: The preparation method further comprises: injecting or dripping the growth factor solution into the loose porous layer of the bone tissue engineering scaffold.
12. The preparation method according to claim 11, characterized in that: The growth factor solution is an IL-10 solution with a concentration of 0.5-1 ng / μL, which is injected or dripped until the growth factor solution completely wets the loose porous layer.
13. The preparation method according to claim 9, characterized in that: The preparation method of the paraffin microspheres is as follows: pouring the paraffin liquid into the polyvinyl alcohol aqueous solution for stirring, pouring into ice water for solidification, washing and screening to obtain the paraffin microspheres with a suitable particle size.
14. Use of the bone tissue engineering scaffold according to any one of claims 1 to 7 in preparing a product for treating bone tissue defects.
Citation Information
Patent Citations
Double-gradient artificial vertebral lamina and preparation method thereof
CN108379665A
Medical periosteum scaffold loaded with ions and geometric pattern signals, and construction method thereof
CN110585487A
Porous composite containing calcium phosphate and process for producing the same
US20060292350A1
Hydroxyapatite based drug delivery implant for cancer treatment
US6767550B1
MY190271A
